Castle Biosciences COO Kristen Oelschlager disposes of 4,153 common shares valued at $148,434
Bitget2026/10/05 20:08Castle Biosciences COO Kristen M. Oelschlager exercised stock options for 4,153 shares at $3.38 on Oct. 1, 2026. She sold 4,153 shares the same day in two blocks, totaling 4,153 shares, at weighted-average prices of $35.75, $36.38. Directly held stake fell to 13,356 shares following the transactions. She also reported 72,649 shares held indirectly through the Fritz Shorter Trust. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-064912), on October 05, 2026, and is solely responsible for the information contained therein.
- Castle Biosciences COO Kristen M. Oelschlager exercised stock options for 4,153 shares at $3.38 on Oct. 1, 2026.
- She sold 4,153 shares the same day in two blocks, totaling 4,153 shares, at weighted-average prices of $35.75, $36.38.
- Directly held stake fell to 13,356 shares following the transactions.
- She also reported 72,649 shares held indirectly through the Fritz Shorter Trust.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.

Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October


SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
